Akari Therapeutics Plc ADR (AKTX)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Increases By 151.7%
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 14,622 shares, a growth of 151.7% from the March 31st total of 5,810 shares. Based on an average trading volume of 45,393 shares, the days-to-cover ratio is presently 0.3
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Akari Therapeutics, PLC (NASDAQ:AKTX) , relating to its proposed merger with Peak Bio, Inc. Under the terms of the agreement, Akari shareholders are expected to own approximately 52% of the combined company.
